Close Menu

NEW YORK – Guardant Health reported after the close of the market on Wednesday that its fourth quarter 2020 revenues rose 25 percent year over year, driven by an increase in clinical testing volumes and revenue.

The Redwood City, California-based cancer genomics and early detection firm said its total revenues for the three months ended Dec. 31, 2020 were $78.3 million compared to $62.9 million in the same quarter of 2019, beating the $76.7 million that Wall Street analysts, on average, had predicted.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.